A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus

The coexistence of cirrhosis complicates the early detection of hepatocellular carcinoma (HCC). Thus, novel biomarkers for HCC early detection are needed urgently. Traditionally, HCC detection is carried out by evaluating alpha-fetoprotein (AFP) levels combined with imaging techniques. This work aim...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Genetic Engineering and Biotechnology 2021-10, Vol.19 (1), p.168-7, Article 168
Main Authors: Omran, Mohamed M, Mosaad, Sara, Emran, Tarek M, Eltaweel, Fathy M, Farid, Khaled
Format: Article
Language:English
Subjects:
Automation
Biomarkers
biotechnology
Blood markers
blood platelet count
Cancer
Chronic illnesses
Cirrhosis
Coexistence
Cytokines
Diagnosis
Glycoproteins
Growth factors
Hepatitis C
Hepatitis C virus
Hepatocellular carcinoma
Hepatoma
Imaging techniques
Insulin
Insulin-like growth factor 2
Insulin-like growth factor II
Insulin-like growth factors
Interleukin
Interleukin 6
Interleukins
Laboratories
Liver
Liver cancer
Liver cirrhosis
Liver diseases
Power
Sensitivity
Thrombocytopenia
Tumor necrosis factor-TNF
Ultrasonic imaging
α-Fetoprotein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The coexistence of cirrhosis complicates the early detection of hepatocellular carcinoma (HCC). Thus, novel biomarkers for HCC early detection are needed urgently. Traditionally, HCC detection is carried out by evaluating alpha-fetoprotein (AFP) levels combined with imaging techniques. This work aimed to assess interleukin (IL-6) and insulin-like growth factor 2 (IGF 2) as possible HCC markers in comparison to AFP in patients with and without HCC. ROC analysis showed that IGF2 had the highest area under the curve (AUC) for discriminating HCC from liver cirrhosis (0.86), followed by IL6 (0.82), AFP (0.72), and platelet count (0.6). A four-marker model was developed and discriminated HCC from liver cirrhosis with an AUC of 0.97. The best cut-off was 1.28, at which sensitivity and specificity were 90% and 85%, respectively. For small tumor (< 2 cm), the model had an AUC of 0.95 compared to AFP (0.72). Also, the model achieved perfect performance with AUC of 0.93, 0.94, and 0.95 for BCLC (0-A), CLIP (0-1), and Okuda (stage I), respectively, compared to AFP (AUC of 0.71, 0.69, and 0.67, respectively). The four markers may serve as a diagnostic model for HCC early stages and help overcome AFP poor sensitivity.
ISSN:1687-157X
2090-5920
DOI:10.1186/s43141-021-00262-8